Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod)
| العنوان: | Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod) |
|---|---|
| المؤلفون: | Cecile N Chougnet, Renaud Ciappuccini, Claire Bournaud, Georges Lion, Laurence Leenhardt, Slimane Zerdoud, David Taïeb, Marie-Claude Eberlé-Pouzeratte, Claire Schvartz, Eliane Le Peillet Feuillet, Inna Dygai-Cochet, Sophie Leboulleux, Olivier Morel, Antony Kelly, Daniela Rusu, B. Catargi, Marmar Kabir-Ahmadi |
| المصدر: | The Journal of Clinical Endocrinology & Metabolism. 104:1020-1028 |
| بيانات النشر: | The Endocrine Society, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Clinical Biochemistry, Thyroid Gland, Thyrotropin, Kaplan-Meier Estimate, Thyroid Function Tests, Biochemistry, Iodine Radioisotopes, 0302 clinical medicine, Endocrinology, Thyroid cancer, medicine.diagnostic_test, Thyroid, Middle Aged, Recombinant Proteins, medicine.anatomical_structure, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Thyroidectomy, Female, medicine.drug, Adult, medicine.medical_specialty, Levothyroxine, Urology, 030209 endocrinology & metabolism, Context (language use), Thyroid function tests, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Thyroid Neoplasms, Neoplasm Staging, Retrospective Studies, business.industry, Biochemistry (medical), Retrospective cohort study, Chemoradiotherapy, Adjuvant, medicine.disease, Thyroxine, Withholding Treatment, Thyroglobulin, business, Follow-Up Studies |
| الوصف: | CONTEXT Recombinant human thyrotropin (rhTSH) has been shown to be an effective stimulation method for radioactive iodine (RAI) therapy in differentiated thyroid cancer, including in those with nodal metastases (N1 DTC). OBJECTIVES To demonstrate the noninferiority of rhTSH vs thyroid hormone withdrawal (THW) in preparation to RAI regarding disease status at the first evaluation in the real-life setting in patients with N1 DTC. DESIGN This was a French multicenter retrospective study. Groups were matched according to age ( 5 lymph nodes), and stage (pT1-T2/pT3). RESULTS The cohort consisted of 404 patients pT1-T3/N1/M0 DTC treated with rhTSH (n = 205) or THW (n = 199). Pathological characteristics and initially administrated RAI activities (3.27 ± 1.00 GBq) were similar between the two groups. At first evaluation (6 to 18 months post-RAI), disease-free status was defined by thyroglobulin levels below threshold and a normal ultrasound. Disease-free rate was not inferior in the rhTSH group (75.1%) compared with the THW group (71.9%). The observed difference between the success rates was 3.3% (-6.6 to 13.0); rhTSH was therefore considered noninferior to THW because the upper limit of this interval was |
| تدمد: | 1945-7197 0021-972X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b782377fa46a1e891ea3f3da3919c9ad https://doi.org/10.1210/jc.2018-01589 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....b782377fa46a1e891ea3f3da3919c9ad |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19457197 0021972X |
|---|